Han, Boram <br/><br/>
A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Nov 2016 
 - 949-958 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-016-3147-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intravenous<br/>Adult<br/>Aged<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Camptothecin--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug Combinations<br/>Female<br/>Gastrointestinal Neoplasms--drug therapy<br/>Humans<br/>Irinotecan<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Oxonic Acid--administration & dosage<br/>Tegafur--administration & dosage<br/>Treatment Outcome